Production and characterization of chimeric monoclonal antibodies against burkholderia pseudomallei and B. mallei using the DHFR expression system

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Kim, Hyung Yong ^a   Tsai, Shien ^a   Lo, Shyh Ching ^b   Wear, Douglas J ^a   Izadjoo, Mina J ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; GLYCOPROTEIN; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; PROTEINASE K; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGEN PURIFICATION; ARTICLE; BURKHOLDERIA MALLEI; BURKHOLDERIA PSEUDOMALLEI; CONTROLLED STUDY; EXPRESSION VECTOR; GENE AMPLIFICATION; GENETIC TRANSFECTION; MOLECULAR SIZE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SEQUENCE ALIGNMENT; WESTERN BLOTTING; AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ANIMAL; BIOSYNTHESIS; CELL CLONE; CHEMISTRY; CHO CELL; CRICETULUS; GENE EXPRESSION; HAMSTER; HUMAN; HYBRIDOMA; IMMUNOLOGY; MAMMAL; METABOLISM; MOLECULAR GENETICS; MOUSE;

BACTERIA (MICROORGANISMS); BURKHOLDERIA; BURKHOLDERIA MALLEI; BURKHOLDERIA PSEUDOMALLEI; BURKHOLDERIA THAILANDENSIS; CRICETULUS GRISEUS; EQUIDAE; MAMMALIA; NEGIBACTERIA;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BURKHOLDERIA MALLEI; BURKHOLDERIA PSEUDOMALLEI; CHO CELLS; CHROMATOGRAPHY, AFFINITY; CLONE CELLS; CRICETINAE; CRICETULUS; GENE EXPRESSION; HUMANS; HYBRIDOMAS; MAMMALS; MICE; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; RECOMBINANT PROTEINS; SEQUENCE ALIGNMENT; TETRAHYDROFOLATE DEHYDROGENASE; TRANSFECTION;

EID: 79955841057     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019867     Document Type: Article

References (44)

1. Leelarasamee A, (2004) Recent development in melioidosis. Curr Opin Infect Dis 17: 131-136.
2. Chaowagul W, White NJ, Dance DAB, Wattanagoon Y, Naigowit P, et al. (1989) Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis 159: 890-899.
3. Leelarasamee A, Bovornkitti S, (1989) Melioidosis: review and update. Rev Infect Dis 11: 413-425.
4. Cheng AC, Currie BJ, (2005) Melioidosis: epidemiology, pathophysiology and management. Clin Microbiol Rev 18: 383-416.
5. Howe C, Miller WR, (1947) Human glanders: report of 6 cases. Ann Intern Med 26: 93-115.
6. White NJ, (2003) Melioidosis. Lancet 361: 1715-1722.
7. Howe C, Sampath A, Spotnitz M, (1971) The pseudomallei group: a review. J Infect Dis 124: 598-606.
8. Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ, (2006) Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev 4: 272-282.
9. Casadevall A, (2002) Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis 8: 833-841.
10. Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389-3402.
11. Rogul M, Brendle JJ, Haapala DK, Alexander AD, (1970) Nucleic acid similarities among Pseudomonas pseudomallei, Pseudomonas multivorans, and Actinobacillus mallei. J Bacteriol 101: 827-835.
12. Reckseidler SL, DeShazer D, Sokol PA, Woods DE, (2001) Detection of bacterial virulence genes by subtractive hybridization: identification of capsular polysaccharide of Burkholderia pseudomallei as a major virulence determinant. Infect Immun 69: 34-44.
13. Cravitz L, Miller WR, (1950) Immunologic studies with Malleomyces mallei and Malleomyces pseudomallei. I. Serological relationships between M. mallei and M. pseudomallei. J Infect Dis 86: 46-51.
14. Brekke OH, Sandlie I, (2003) Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev 2: 52-62.
15. Vaughan TJ, Osbourn JK, Tempest PR, (1998) Human antibodies by design. Nat Biotechnol 16: 535-539.
16. Feng S-H, Tsai S, Rodriguez J, Newsome T, Emanuel P, et al. (2006) Development of mouse hybridomas for production of monoclonal antibodies specific to Burkholderia mallei and Burkholderia pseudomallei. Hybridoma (Larchmt) 25: 193-201.
17. Zou N, Tsai S, Feng S-H, Newsome T, Kim H-Y, et al. (2008) Relationship between antigenicity and pathogenicity for Burkholderia pseudomallei and Burkholderia mallei revealed by a large panel of mouse monoclonal antibodies. Hybridoma (Larchmt) 27: 231-240.
18. Zhang S, Feng SH, Li B, Kim H-Y, Rodriguez J, et al. (2011) In vitro and in vivo studies on monoclonal antibodies with prominent bactericidal activity against Burkholderia pseudomallei and Burkholderia mallei. Clin Vaccine Immunol doi:10.1128/CVI.00533-10.
19. Jones SM, Ellis JF, Russel P, Griffin KF, Oyston PCF, (2002) Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins. J Med Microbiol 51: 1055-1062.
20. Treviño SR, Permenter AR, England MJ, Parthasarathy N, Gibbs PH, et al. (2006) Monoclonal antibodies passively protect BALB/c mice against Burkholderia mallei aerosol challenge. Infect Immun 74: 1958-1961.
21. Chan S-W, Ong G-I, Nathan S, (2004) Neutralizing chimeric mouse-human antibodies against Burkholderia pseudomallei protease: Expression, purification and characterization. Biochem Mol Biol 37: 556-564.
22. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, et al. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445.
23. Bianchi AA, McGrew JT, (2003) High-level expression of full-length antibodies using trans-complementing expression vectors. Biotechnol Bioeng 84: 439-444.
24. Kim SJ, Kim NS, Ryu CJ, Hong HJ, (1997) Characterization of chimeric antibody producing CHO cells in the course of the dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressure. Biotechnol Bioeng 58: 73-84.
25. Lucas BK, Giere LM, DeMarco RA, Shen A, Chisholm V, et al. (1996) High-level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector. Nucleic Acids Res 24: 1774-1779.
26. Kim H-Y, Rikihisa Y, (2002) Roles of p38 mitogen-activated and protein-activated protein kinase C in proinflammatory cytokine mRNA expression by human peripheral blood leukocytes, monocytes and neutrophils in response to Anaplasma phagocytophila. Infect Immun 70: 4132-4141.
27. Ryan MD, King AMQ, Thomas GP, (1991) Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J Gen Virol 72: 2727-2732.
28. Vernel-Pauillac F, Merien F, (2006) Proinflammatory and immunomodulatory cytokine mRNA time course profiles in hamsters infected with a virulent variant of Leptospira interrogans. Infect Immun 74: 4172-4179.
29. Kim H-Y, Rikihisa Y, (1998) Characterization of monoclonal antibodies to the 44-kilodalton major outer membrane protein of the human granulocytic ehrlichiosis agent. J Clin Microbiol 36: 3278-3284.
30. Dinnis DM, James DC, (2005) Engineering mammalian cell factories for improved recombinant monoclonal antibody production: lessons from nature? Biotechnol Bioeng 91: 180-189.
31. Werner RG, Noé W, Kopp K, Schlüter M, (1998) Appropriate mammalian expression systems for biopharmaceuticals. Arzneim-Forsch/Drug Res 48: 870-880.
32. Orlandi R, Güssow DH, Jones PT, Winter G, (1989) Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci USA 86: 3833-3837.
33. Walls MA, Hsiao K-C, Harris LJ, (1993) Vectors for the expression of PCR-amplified immunoglobulin variable domains with human constant regions. Nucleic Acids Res 21: 2921-2929.
34. Chinnasamy D, Milsom MD, Shaffer J, Neuenfeldt J, Shaaban AF, et al. (2006) Muticistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI. Virology Journal 3: 1-16.
35. Fang J, Qian J-J, Yi S, Harding TC, Tu GH, et al. (2005) Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 23: 584-590.
36. Chusainow J, Yang YS, Yeo JH, Toh PC, Asvadi P, et al. (2009) A study of monoclonal antibody-producing CHO cell lines: what makes a stable high producer? Biotechnol Bioeng 102: 1182-1196.
37. Woodward MP, Young WW Jr, Bloodgood RA, (1985) Detection of monoclonal antibodies specific for carbohydrate epitopes using periodate oxidation. J Immunol Methods 78: 143-153.
38. Wurm FM, (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22: 1393-1398.
39. Bondi SK, Goldberg JB, (2008) Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei. Expert Rev Vaccines 7: 1357-1365.
40. Felgner PL, Kayala MA, Vigil A, Burk C, Nakajima-Sasaki R, et al. (2009) A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigens. Proc Natl Acad Sci USA 106: 13499-13504.
41. Hara Y, Mohamed RS, Nathan S, (2009) Immunogenic Burkholderia pseudomallei outer membrane proteins as potential candidate vaccine targets. PLoS One 4: e6496.
42. Nelson M, Prior JL, Lever MS, Jones HE, Atkins TP, et al. (2004) Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J Med Microbiol 53: 1177-1182.
43. Plesa M, Kholti A, Vermis K, Vandamme P, Panagea S, et al. (2004) Conservation of the opcL gene encoding the peptidoglycan-associated outer-membrane lipoprotein among representatives of the Burkholderia cepacia complex. J Med Microbiol 53: 389-398.
44. Zhang H, Niesel DW, Peterson JW, Klipel GR, (1998) Lipoprotein release by bacteria: potential factor in bacterial pathogenesis. Infect Immun 66: 5196-5201.